{
  "docId": "019dd923-5fed-74f2-a96f-1bdfa0f8925c",
  "docSlug": "bi-42cd9f0525110ab4",
  "documentTitle": "Here's dermatology startup Zerigo's Series B pitch deck",
  "authorId": "Pitchdecks",
  "authorName": "Zerigo Health",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.784,
  "pageNumber": 10,
  "pageCount": 17,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The chart shows a cumulative cost projection reaching over $219M for 25 new members per month over 5 years.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "area_chart",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fed-74f2-a96f-1bdfa0f8925c/10",
  "deckHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c",
  "deckJsonHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c.json",
  "deckAnchorHref": "/decks/019dd923-5fed-74f2-a96f-1bdfa0f8925c#slide-10",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "If only 25 new members initiate biologic therapy each month, an additional 1,500 members will be on biologics in 5 years, with cumulative costs in excess of $200M over the 5-year period.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-b667-711e-a961-8a0fb0133e24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Cumulative Biologics Costs for a Population of Psoriasis Patients",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05cf6c64-6c9e-4886-b3c0-ae6263d3ea0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.065
      },
      "kind": "list",
      "text": "Within any given population of Psoriasis patients, approximately 75% have mild-moderate psoriasis. For a plan with 1M members, this equates to ~23K members with mild-moderate PsO. If only 25 new members initiate biologic therapy each month, an additional 1,500 members will be on biologics in 5 years, with cumulative costs in excess of $200M over the 5-year period.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21344bd3-8b58-4375-9fa6-b9478ef48487",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Cumulative Biologics Costs: $219,092,000",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-b667-711e-a961-8f631965eeb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data 2. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d16b404-8a9b-483e-82fc-cbd0be7dd20a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "The Cost of Biologics is Staggering for Health Plans & Self-Insured Employers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9388760f-eca4-4f05-912a-f32d8da0318d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "3222ecd1-aa67-41ad-913e-0e1efb2955e9",
      "evidence": "chart/area: Cumulative Biologics Costs for a Population of Psoriasis Patients",
      "confidence": 0.5
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "6ac50216-b09c-4cff-8f4b-97257c34023b",
      "evidence": "The Cost of Biologics is Staggering for Health Plans & Self-Insured Employers",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "065c9a5b-fd58-4fdf-b24c-97ee5669638d",
      "evidence": "Slides 7-10 discuss the cost of biologics and the need for alternative solutions",
      "position": 0,
      "objective": "Highlight the cost burden of biologics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}